JCC:Prox1表达下降与克罗恩病术后复发相关

2018-07-02 MedSci MedSci原创

Prox1是淋巴管生成和淋巴液产生功能所必需的转录因子。本项研究探讨了Prox1的表达水平与克罗恩病(CD)术后复发之间的相关性。

背景
Prox1是淋巴管生成和淋巴液产生功能所必需的转录因子。本项研究探讨了Prox1的表达水平与克罗恩病(CD)术后复发之间的相关性。

方法
本项研究纳入了接受回肠结肠切除术的40名CD患者。使用免疫组织化学检测Prox1和D2-40的表达水平。Prox1,VEGFR3和VEGFC蛋白的表达水平也使用western印迹和Q-PCR在CD样品中进行检测。内镜复发作为本项研究的观察终点。患者被分为两组:内镜复发(R +组)和无内镜复发(R-组)。

结果
使用免疫组织化学和蛋白质印迹法检测Prox1结果表明CD中Prox1蛋白表达显着高于正常组织(P <0.05)。皮尔逊相关分析揭示了Prox1表达与淋巴管密度之间的显着相关性(P <0.001,r = 0.823)。Prox1表达与内脏脂肪面积(VFA)也有显着相关性(P = 0.002,r = -0.469)。(R-组)患者的Prox1表达显着高于(R +组)患者(21.08±1.61 vs. 15.64±1.17,P = 0.011)。此外,(R-)组患者的淋巴管密度值低于(R+)组患者(6.02±0.39比8.13±0.59,P = 0.004)。此外,(R-组)和(R +组)患者的VFA差异有统计学意义(64.43±7.76比90.44±6.11,P = 0.016)。

结论
Prox1高表达可作为CD患者复发的保护因子。Prox1也许可以作为今后克罗恩病治疗的新靶点。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991820, encodeId=d8b11991820c7, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Mon Aug 27 19:12:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791805, encodeId=df161e91805fd, content=<a href='/topic/show?id=ce1a14e758a' target=_blank style='color:#2F92EE;'>#Prox1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14775, encryptionId=ce1a14e758a, topicName=Prox1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri Apr 19 10:12:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602024, encodeId=1164160202428, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jul 04 02:12:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328715, encodeId=6d89328e15f1, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jul 02 12:09:08 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328706, encodeId=79f4328e06ff, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jul 02 11:44:58 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1991820, encodeId=d8b11991820c7, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Mon Aug 27 19:12:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791805, encodeId=df161e91805fd, content=<a href='/topic/show?id=ce1a14e758a' target=_blank style='color:#2F92EE;'>#Prox1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14775, encryptionId=ce1a14e758a, topicName=Prox1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri Apr 19 10:12:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602024, encodeId=1164160202428, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jul 04 02:12:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328715, encodeId=6d89328e15f1, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jul 02 12:09:08 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328706, encodeId=79f4328e06ff, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jul 02 11:44:58 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2019-04-19 zz12341234
  3. [GetPortalCommentsPageByObjectIdResponse(id=1991820, encodeId=d8b11991820c7, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Mon Aug 27 19:12:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791805, encodeId=df161e91805fd, content=<a href='/topic/show?id=ce1a14e758a' target=_blank style='color:#2F92EE;'>#Prox1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14775, encryptionId=ce1a14e758a, topicName=Prox1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri Apr 19 10:12:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602024, encodeId=1164160202428, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jul 04 02:12:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328715, encodeId=6d89328e15f1, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jul 02 12:09:08 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328706, encodeId=79f4328e06ff, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jul 02 11:44:58 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2018-07-04 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1991820, encodeId=d8b11991820c7, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Mon Aug 27 19:12:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791805, encodeId=df161e91805fd, content=<a href='/topic/show?id=ce1a14e758a' target=_blank style='color:#2F92EE;'>#Prox1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14775, encryptionId=ce1a14e758a, topicName=Prox1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri Apr 19 10:12:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602024, encodeId=1164160202428, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jul 04 02:12:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328715, encodeId=6d89328e15f1, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jul 02 12:09:08 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328706, encodeId=79f4328e06ff, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jul 02 11:44:58 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2018-07-02 清风拂面

    谢谢分享学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1991820, encodeId=d8b11991820c7, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Mon Aug 27 19:12:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791805, encodeId=df161e91805fd, content=<a href='/topic/show?id=ce1a14e758a' target=_blank style='color:#2F92EE;'>#Prox1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14775, encryptionId=ce1a14e758a, topicName=Prox1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri Apr 19 10:12:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602024, encodeId=1164160202428, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jul 04 02:12:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328715, encodeId=6d89328e15f1, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jul 02 12:09:08 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328706, encodeId=79f4328e06ff, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jul 02 11:44:58 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2018-07-02 天地飞扬

    了解一下.谢谢分享!

    0

相关资讯

GUT:携带IL-23受体的TNFR2 + T细胞的扩增与克罗恩病中抗TNF治疗的分子抗性相关

抗肿瘤坏死因子(TNF)治疗克罗恩病目前在临床工作中取得了巨大成功。然而,大约40%的患者会出现抗TNF治疗的失败。在这里,研究人员进行了与抗TNF治疗失败的抗性相关的分子机制的研究。

Clin Gastroenterol H:患有炎症性肠病的原发性硬化性胆管炎患者发生进展性结肠癌的风险增加

炎性肠病(IBD)伴发原发性硬化性胆管炎(PSC,称为PSC-IBD)的患者出现结肠直肠癌的风险增加,但当患者被诊断为低度不典型增生(LGD)后的疾病如何进展目前尚不明确。本项研究旨在确定在PSC-IBD群体中从高度发育不良进展为结肠直肠癌的晚期结肠直肠肿瘤(aCRN)的情况。

Dig Dis & Sci:小肠细菌过度生长与炎症性肠病患者的症状严重程度相关

在炎症性肠病(IBD)中,抑制小肠细菌过度生长(SIBO)的常见机制包括完整的回盲瓣,胃酸分泌,肠道蠕动和完整的免疫系统,因此SIBO发病率在缺少这些机制的CD患者中相对较高。本项研究旨在确定是否通过减少SIBO来减轻IBD临床活动。

WJG:磁共振成像和克罗恩病内镜严重度指数的相关性及一致性的研究

克罗恩病患者的疾病严重可以通过内镜检查进行判断,但是在临床工作实施难度较大。本研究希望将克罗恩病(CD)患者的磁共振成像(MRI)与内镜下严重程度指数(CDEIS)进行相关性分析,以期获得一种非侵入性快速检查方法。

Dig Dis & Sci:炎症性肠病患者使用抗肿瘤坏死因子会增加银屑病相关的发生率

有越来越多地报道证明抗-TNF制剂对患有银屑病的CD患者治疗效果欠佳。本项研究就将炎症性肠病患者中大量使用抗TNF相关性银屑病的患病率和临床特征进行分析。

Dig Dis & Sci:结肠克罗恩病相比于回肠或回结肠疾病相比疾病表现更温和。

目前有关结肠克罗恩病(CD)疾病特征的文献很少,尤其是在亚洲,炎症性肠病的负担在上升。本研究旨在描述结肠CD的疾病特征,并将其与回肠/回肠结肠克罗恩病的特征进行比较。